Immunotech Laboratories, Inc. has issued an exclusive Distribution Agreement for the territory of the Ukraine to LLC Project Development and Implementation Centre Omega. The term of the agreement is for an initial ten-year period with an option to renew the agreement for an additional ten years. The Agreement establishes a price of EUR 3,300 per one 8-week cycle of injections or 16 vials. The treatment protocol requires two 8-week cycles of injections administered twice a week with a one-week break between cycles. The ITV-1 treatment will be administered with a combination of different variations of Protease Inhibitors used in the treatment of HIV/AIDS. The Agreement established a minimum order as 50 doses of the treatment, or 800 vials. The first order placed is for 10,000 units which will undergo manufacturing validation and then delivered to Omega for sale in the Ukraine as soon as the manufacturing permit is issued, which is expected within the next 180 days. This initial validation order is valued at EUR 2,062,500. The validation documentation will be completed in batches of 3,300 and necessary documentation to complete the registration process is anticipated to be completed and delivered to the Bulgarian Drug Administration (BDA) by the end of September. Upon successful completion of the validation and review of the resulting documentation by the BDA, the Company expects the permit for the mass production and sale in the EU to be issued. Completion of the process will allow the treatment to be sold throughout the EU and wherever the permit issued by the BDA is recognized, including the Ukraine. The Company expects additional orders to be placed in similar quantities on a monthly basis after the issuance of the permit.

The company also announced that the US Patented ITV-1 treatment has successfully completed Phase I, II and III clinical testing in Sofia, Bulgaria through Immunotech Laboratories BG -- Europe LTD, a subsidiary of the acquired entity. The Phase III testing was conducted at the National Center of Infectious and Parasitic Diseases in Sofia, Bulgaria on a test group of salvage patients suffering from advanced stages of HIV/AIDS using the best modern testing procedures as approved at the latest World Practice Conference. The final report issued by the Ministry of Health demonstrated improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK and of the index CD4/CD8, significant decreases in viral load, a good treatment effect on opportunistic infections, compatibility with all of the other modern antiretroviral drugs, and exceptional tolerance in all patients with a complete absents of any major side effects. The treatment did not show any signs of treatment failure due to the development of resistance or toxicity during the Phase III trials as is often the case with the current medications available in the market today. Approximately 80% of the test subjects reported viral loads at a nil level as a result of the treatment with approximately 67% of the test subjects showing an improved Immune system.